```
FILE 'HOME' ENTERED AT 10:16:56 ON 20 NOV 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:17:01 ON 20 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 NOV 2006  HIGHEST RN 913611-00-4
DICTIONARY FILE UPDATES:  19 NOV 2006  HIGHEST RN 913611-00-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> E "REBOXETINE"/CN 25
E1            1     REBOUL COCKTAIL/CN
E2            1     REBOUND/CN
E3            1 --> REBOXETINE/CN
E4            1     REBOXETINE FUMARATE/CN
E5            1     REBOXETINE HYDROBROMIDE/CN
E6            1     REBOXETINE MESYLATE/CN
E7            1     REBOXITINE/CN
E8            1     REBRAMIN/CN
E9            1     REBRIDEN/CN
E10           1     REBUILDA/CN
E11           1     REBULAC/CN
E12           1     REBULITE/CN
E13           1     REBULITE (SB5AS8TL5S22)/CN
E14           1     REBUS 1106/CN
E15           1     REBUS BLACK 2101/CN
E16           1     REBUS BLACK 2106/CN
E17           1     REBUS BLACK 2125/CN
E18           1     REBUS CARBON BLACK 1106/CN
E19           1     REBUS GREEN 1750/CN
E20           1     REBUS HIGH STRENGTH BLACK 2125/CN
E21           1     REBUSO/CN
E22           1     REC/CN
E23           1     REC (HUMAN CLONE MGC:21181 IMAGE:4398300)/CN
E24           1     REC (HUMAN CLONE MGC:33737 IMAGE:5299722)/CN
E25           1     REC (RECEIVER) DOMAIN SIGNAL TRANSDUCTION PROTEIN (PEDIOCOCCUS
PENTOSACEUS STRAIN ATCC 25745)/CN

=> S E3
L1            1 REBOXETINE/CN

=> DIS L1 1 IDE
```

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 71620-89-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Reboxetine
CN Reboxitine
FS STEREOSEARCH
DR 98769-81-4, 98769-83-6, 71621-36-8
MF C19 H23 N O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

370 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
375 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 79617-96-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S,4S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)-
OTHER NAMES:
CN (+)-Sertraline
CN (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
CN (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine
CN CP 51974
CN Sertraline
FS STEREOSEARCH
MF C17 H17 Cl2 N
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1517 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1527 REFERENCES IN FILE CAPLUS (1907 TO DATE)

THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 71620-89-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-rel- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Reboxetine
CN Reboxitine
FS STEREOSEARCH
DR 98769-81-4, 98769-83-6, 71621-36-8
MF C19 H23 N O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

370 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
375 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "REBOXETINE"/CN 25

E1	1	REBOUL COCKTAIL/CN
E2	1	REBOUND/CN
E3	1 -->	REBOXETINE/CN
E4	1	REBOXETINE FUMARATE/CN
E5	1	REBOXETINE HYDROBROMIDE/CN
E6	1	REBOXETINE MESYLATE/CN
E7	1	REBOXITINE/CN
E8	1	REBRAMIN/CN
E9	1	REBRIDEN/CN
E10	1	REBUILDA/CN
E11	1	REBULAC/CN
E12	1	REBULITE/CN
E13	1	REBULITE (SB5AS8TL5S22)/CN
E14	1	REBUS 1106/CN
E15	1	REBUS BLACK 2101/CN
E16	1	REBUS BLACK 2106/CN
E17	1	REBUS BLACK 2125/CN
E18	1	REBUS CARBON BLACK 1106/CN
E19	1	REBUS GREEN 1750/CN
E20	1	REBUS HIGH STRENGTH BLACK 2125/CN
E21	1	REBUSO/CN

```
E22             1     REC/CN
E23             1     REC (HUMAN CLONE MGC:21181 IMAGE:4398300)/CN
E24             1     REC (HUMAN CLONE MGC:33737 IMAGE:5299722)/CN
E25             1     REC (RECEIVER) DOMAIN SIGNAL TRANSDUCTION PROTEIN (PEDIOCOCCUS
PENTOSACEUS STRAIN ATCC 25745)/CN

=> E "SERTRALINE"/CN 25
E1              1     SERTOLIN (RAT SERTOLI CELL)/CN
E2              1     SERTOLIN (RATTUS NORVEGICUS SERTOLI CELL)/CN
E3              1 --> SERTRALINE/CN
E4              1     SERTRALINE CARBAMOYL-O-GLUCURONIDE/CN
E5              1     SERTRALINE HYDROCHLORIDE/CN
E6              1     SERTRALINE HYDROCHLORIDE ETHANOLATE/CN
E7              1     SERTRALINE HYDROCHLORIDE METHANOLATE/CN
E8              1     SERTRALINE HYDROCHLORIDE MONOHYDRATE/CN
E9              1     SERTRALINE MANDELATE/CN
E10             1     SERTRALINE TETRALONE/CN
E11             1     SERTRALONE/CN
E12             1     SERTUERNER/CN
E13             1     SERTULARAMIDE/CN
E14             1     SERTUM/CN
E15             1     SERU-D ANTIGEN (FLAG ROCKFISH CLONE 01 GENE SERU-DAB SUBUNIT B
FRAGMENT)/CN
E16             1     SERU-D ANTIGEN (FLAG ROCKFISH CLONE 03 GENE SERU-DAB SUBUNIT B
FRAGMENT)/CN
E17             1     SERU-D ANTIGEN (FLAG ROCKFISH CLONE 04 GENE SERU-DAB SUBUNIT B
FRAGMENT)/CN
E18             1     SERU-D ANTIGEN (FLAG ROCKFISH CLONE 05 GENE SERU-DAB SUBUNIT B
FRAGMENT)/CN
E19             1     SERU-D ANTIGEN (FLAG ROCKFISH CLONE 06 GENE SERU-DAB SUBUNIT B
FRAGMENT)/CN
E20             1     SERU-D ANTIGEN (FLAG ROCKFISH CLONE 07 GENE SERU-DAB SUBUNIT B
FRAGMENT)/CN
E21             1     SERU-D ANTIGEN (FLAG ROCKFISH CLONE 09 GENE SERU-DAB SUBUNIT B
FRAGMENT)/CN
E22             1     SERU-D ANTIGEN (SEBASTES RUBRIVINCTUS CLONE 01 GENE SERU-DAB
SUBUNIT B FRAGMENT)/CN
E23             1     SERU-D ANTIGEN (SEBASTES RUBRIVINCTUS CLONE 03 GENE SERU-DAB
SUBUNIT B FRAGMENT)/CN
E24             1     SERU-D ANTIGEN (SEBASTES RUBRIVINCTUS CLONE 04 GENE SERU-DAB
SUBUNIT B FRAGMENT)/CN
E25             1     SERU-D ANTIGEN (SEBASTES RUBRIVINCTUS CLONE 05 GENE SERU-DAB
SUBUNIT B FRAGMENT)/CN

=> S E3
L2              1 SERTRALINE/CN

=> DIS L2 1 IDE
THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   79617-96-2  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-,
     (1S,4S)-  (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-,
     (1S-cis)-
OTHER NAMES:
CN   (+)-Sertraline
CN   (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-
     naphthalenamine
CN   (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-
```

naphthaleneamine
CN CP 51974
CN Sertraline
FS STEREOSEARCH
MF C17 H17 Cl2 N
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1517 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1527 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.64	14.85

FILE 'CAPLUS' ENTERED AT 10:18:47 ON 20 NOV 2006

FILE COVERS 1907 - 20 Nov 2006 VOL 145 ISS 22
FILE LAST UPDATED: 19 Nov 2006 (20061119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 71620-89-8
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L4   375 L3

=> s 79617-96-2
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6   1527 L5

=> l4(s)l6
L4(S)L6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l4(s)l6
L7   0 L4(S)L6

=> s l4(p)l6
L8   0 L4(P)L6

=> s l4 and l6
L9   82 L4 AND L6

=> s l4(n)l6
L10   0 L4(A)L6

=> d l9 ti au so py abs 1-10

L9   ANSWER 1 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI   Method and medicinal composition for curing neurasthenia and somatoform
     disorder
IN   Liu, Ping; Yu, Duo; Long, Haizhen; Li, Jintong; Li, Hua; Wang, Yu; Dai,
     Chengxiang; Chen, Guangliang; Xing, Houxun; Xu, Xiping
SO   Faming Zhuanli Shenqing Gongkai Shuomingshu, 21pp.
     CODEN: CNXXEV
PY   2006

AB The medicinal composition for curing neurasthenia and somatoform disorder comprises medicinal dosage selective norepinephrine reuptake inhibitor or its medicinal salts and medicinal dosage selectivity 5-hydroxytryptamine or its medicinal acceptable salt composition The norepinephrine reuptake inhibitor comprises Tomoxetine, reboxetine, bupropion, imipramine, desipramine, amitriptyline, nortriptyline, maprotiline and protriptyline, and reboxetine methane sulfonate. The 5-hydroxytryptamine comprises fluoxetine, Sertraline, citalopram, paroxetine, fluvoxamine, Sertraline hydrochloride, citalopram hydrobromide. The medicinal composition is prepared into oral preparation, i.v. injection or suppository. The somatoform disorder comprises Somatization disorder, hypochondria, somatoform autonomic dysfunction, Persistent Somatoform Pain Disorder.

L9 ANSWER 2 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of amino acid derivatives with high therapeutic index
IN Chandran, V. Ravi
SO U.S. Pat. Appl. Publ., 139pp.
CODEN: USXXCO
PY 2006
2005
AB The invention is directed to novel therapeutic compds. comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating function. These high-therapeutic index derivs. have the same utility as the drug from which they are made and they have enhanced pharmacol. and pharmaceutical properties. The examples describe the synthesis and activities of amino acid derivs. of propofol, ibuprofen, ketoprofen, ketorolac, aspirin, acetaminophen, cyclosporin A, valproic acid, clopidogrel, damazol, benzapril, enalapril, and fenofibric acid. Thus, (±)-ibuprofen esters of L-serine, L-threonine, and L-hydroxyproline were prepared and examined for analgesic, gastric mucosal irritation, toxicity, and pharmacokinetic properties.

L9 ANSWER 3 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, single-sample approach
AU Kirchherr, H.; Kuehn-Velten, W. N.
SO Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2006), 843(1), 100-113
CODEN: JCBAAI; ISSN: 1570-0232
PY 2006
AB This method describes the simultaneous determination of amisulpride, amitriptyline, aripiprazole, benperidol, chlorpromazine, chlorprothixene, citalopram, clomipramine, clozapine, desipramine, doxepin, fluoxetine, flupentixol, fluphenazine, fluvoxamine, haloperidol, hydroxyrisperidone, imipramine, levomepromazine, maprotiline, mianserine, mirtazapine, moclobemide, norclomipramine, nordoxepin, norfluoxetine, nortriptyline, O-desmethylvenlafaxine, olanzapine, opipramol, paroxetine, perazine, perphenazine, pimozide, pipamperone, quetiapine, reboxetine, risperidone, sertraline, sulpiride, thioridazine, trazodone, trimipramine, venlafaxine, viloxazine, ziprasidone, zotepine and zuclopenthixol with a single sample/triple injection approach. Drugs were assigned to subgroups covering low, medium and high concns. (overall range of therapeutic levels to be considered: 0.5-2000 ng/mL) by further dilution of the supernatant obtained after the first protein precipitation Chromatog. separation was necessary for isobaric mass fragments and performed on a monolithic C18 column (50 mm + 4.6 mm) with methanol gradient and 5 mM acetate buffer at pH 3.9. The injection interval was 8 min. A set of three internal stds. was used for quantification of drugs with widely varying hydrophobicity. After electrospray ionization pos. ion fragments were detected in the multiple reaction monitoring mode with an API 4000 tandem mass spectrometer. Regression parameters of calibration curves and limits of quantification showed good covering of therapeutic and subtherapeutic ranges with an average

correlation coefficient of 0.9988. Imprecision and inaccuracy measures were prepared for intra- and inter-assay comparisons at three concentration ranges in all subgroups. Average coeffs. of variation were 6.1% for intra-assay and 7.4% for inter-assay comparisons, while average deviations from spiked concns. were 4.8% for intra-assay and 4.2% for inter-assay comparisons, resp. Recovery rates, measured as the percent recoveries of spiked serum samples against standard solns. without serum matrix, varied between 92 and 111%, with an average of 101%. As the only exception, the olanzapine response was much higher (185%) in serum matrix than in matrix-free controls.

L9 ANSWER 4 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions for the treatment and/or prevention of depression
IN Pyke, Robert; Ceci, Angelo
SO PCT Int. Appl., 30pp.
CODEN: PIXXD2
PY 2006
2006
AB The invention relates to new pharmaceutical compns. for the treatment and/or prevention of depression and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one addnl. active ingredient for the treatment and/or prevention of depression and methods for the preparation thereof.

L9 ANSWER 5 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of spiro[cyclohexane-1,4'-quinazoline] derivatives for use as PDE7 inhibitors for the treatment of neuropathic pain
IN Cox, Peter; Kinloch, Ross Anderson; Maw, Graham Nigel
SO PCT Int. Appl., 108pp.
CODEN: PIXXD2
PY 2006
2006
GI





IV

AB Compds. I-III [Ring B = (un)substituted six-membered aryl or heteroaryl ring; Ring A = (un)substituted spirocycle or spiroheterocycle; X = O or NH, NNH2, etc.; Y = O, S, NH, etc.; Z = CHNO2, O, S, etc.; Z1 = H, Me, NH2, etc.] are disclosed as phosphodiesterase 7 (PDE7) inhibitors for use in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an inhibitor of PDE7. Methods for preparing title compds. are given. Thus, e.g., IV was prepared by substitution of trans-3-[(benzyloxy)methyl]cyclobutyl p-toluenesulfonate (preparation given) with 8'-chloro-5'-hydroxy-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one followed by deprotection and oxidation In PDE7A inhibition assays, IV demonstrated a Ki value of 1.9 (nM).

L9 ANSWER 6 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method and device for ophthalmic administration of active pharmaceutical ingredients
IN Gross, Yossi; Herzog, Rafi; Koevary, Steven B.
SO PCT Int. Appl., 127pp.
CODEN: PIXXD2
PY 2006
AB Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and a carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterilizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered drug in a pharmaceutical composition

L9 ANSWER 7 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions using cyclooxygenase 2 (COX-2) inhibitors for the treatment of psychiatric disorders, and combination therapies
IN Muller, Norbert
SO U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 157,969.
CODEN: USXXCO
PY 2006
2003
2006
2006
AB A method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia, is described which comprises administering a COX-2 inhibitor or prodrug thereof to a subject. Moreover, a method for the prevention, treatment, or inhibition of a psychiatric disorder, in particular schizophrenia or depressive disorders, is disclosed comprising administering to a subject a COX-2 inhibitor or prodrug thereof in combination with a neuroleptic drug or an antidepressant. Compns. and kits that are suitable for the practice of the method are also described.

L9 ANSWER 8 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions comprising an agent with serotonin receptor modulating activity for sleep disorders
IN Rariy, Roman V.; Heffernan, Michael
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
PY 2006
AB Pharmaceutical compns. are provided for the pharmacol. treatment of breathing disorders and, more specifically, to compns. containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing

disorders wherein the active ingredients are released such as to extend effective blood plasma concns. across the period of sleep. For example, ondansetron immediate release tablets were prepared containing ondansetron HCl dihydrate 9.98 mg, lactose 29.14 mg, Prosolv 50 29.14 mg, Ac-Di-Sol 3.75 mg, SDS 1.5 mg, Aerosil 0.75 mg, and Mg stearate 0.75 mg. Ondansetron immediate release tablets were then coated with Eudragit L100/S100 blend to obtain delayed release tablets.

L9 ANSWER 9 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Serotonin transporter polymorphisms and side effects in antidepressant therapy - a pilot study
AU Popp, Johannes; Leucht, Stefan; Heres, Stephan; Steimer, Werner
SO Pharmacogenomics (2006), 7(2), 159-166
CODEN: PARMFL; ISSN: 1462-2416
PY 2006
AB Objectives: To assess the influence of the serotonin transporter variable number of tandem repeat (HTT-VNTR) polymorphism and the serotonin transporter-gene-linked polymorphic region (HTTLPR) polymorphism on development of side effects under antidepressant therapy. Methods: A total of 109 depressive in-patients treated with various antidepressants according to local clin. practice were included in the investigation. Four weeks after admission to hospital, side effects were assessed by using a modified version of the dosage record and treatment emergent symptoms scale (DOTES). Differences in side effects between the genotype groups of both polymorphisms were analyzed using the Fisher's exact test. Results: A total of 65 patients received mirtazapine (25 of them in combination with other antidepressants), and 44 patients were predominantly treated with antidepressants acting via HTT, such as selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). When patients were treated with HTT-blocking antidepressants, a significantly higher occurrence of side effects in patients with the HTTVNTR 2.10/2.10 genotype (52.6%) than in patients with the 2.10/2.12 (12.5%) and 2.12/2.12 (0%) genotypes ($p = 0.004$) was found. With regard to the HTTLPR polymorphism, patients predominantly on HTT-blocking antidepressants with the s/s genotype suffered more frequently from side effects (50.0%) than heterozygotes (40.0%) and homozygotes for the I-allele (0%) ($p = 0.002$). In contrast, no association of the HTTVNTR polymorphism was found in patients treated with mirtazapine. The risk groups defined by a combined genotype from both polymorphisms demonstrated a major effect on the incidence of adverse drug events in patients treated with predominantly HTT-blocking antidepressants ($p = 0.00018$; low risk: 0%, 0/13, medium risk: 13.3%, 2/15, high risk: 62.5%, 10/16). Conclusion: These results support the hypothesis that both polymorphisms influence tolerability to drugs primarily acting via HTT inhibition, such as SSRIs, TCAs and venlafaxine. Tolerability to mirtazapine was not influenced, probably owing to a different mode of action. As there are limitations due to the heterogeneity of treatment and concomitant therapy, further studies are required to confirm the obtained results.

L9 ANSWER 10 OF 82 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods for regulating neurotransmitter systems by inducing counteradaptations
IN Michalow, Alexander
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
PY 2006
2006
2006
AB The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to

period between administrations of no greater than 1/2. The methods of the present invention may be used to address a whole host of undesirable mental and neurol. conditions.

```
=> s l4(l)l6
L11           0 L4(L)L6

=>
```

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	682	norepinephrine adj reuptake adj inhibitor	US-PGPUB; USPAT; EPO; JPO; DERWENT	ADJ	ON	2006/11/20 11:11
L2	2835	selective adj serotonin adj reuptake adj inhibitor or SSRI	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2006/11/20 11:12
L3	269	l1 with l2	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/20 11:12
L4	0	l1 with l2 @py<="2003"	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/20 11:12
L5	0	l1 same l2 @py<="2003"	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/20 11:13
L6	313	l1 same l2	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/20 11:13
S1	736	nicotine near withdraw$4	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2006/11/20 11:10
S2	514	reboxetine	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/11/17 16:07
S3	3343	sertraline	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/11/17 16:07
S4	10	S1 and S2 and S3	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/11/17 16:10
S5	200	S2 same S3	US-PGPUB; USPAT; EPO; JPO; DERWENT	SAME	ON	2006/11/20 09:58

EAST Search History

S6	514	reboxetine	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/11/20 09:58
S7	3346	sertraline	US-PGPUB; USPAT; EPO; JPO; DERWENT	AND	ON	2006/11/20 09:58
S8	151	S6 with S7	US-PGPUB; USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/20 10:03
S9	28	S6 with S7	USPAT; EPO; JPO; DERWENT	WITH	ON	2006/11/20 10:03